Cell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products

Similar documents
Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks

Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

Elwyn Griffiths, DSc, PhD, UK

Development. - Be Your Partner-

European Guideline for Virus Safety Evaluation of Clinical Trial Material

Critical Quality Attributes for Live Viral Vaccines. Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA

LONG R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications

Biopharmaceutical Drugs

Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences

Lentiviral Vector Reference Material (LVV RM) Request for Proposal RFP 1.0 Vector Production and Purification

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM

Biosafety Considerations for Cell Based Viral Vaccines. Margaret Temple SGS Vitrology Site Director Glasgow - UK

Accelerated Path to Probe Biology through Deferred Cloning and Applying Platform Manufacturing Processes

The Elite Provider. Cell & Gene. Therapy Manufacturing

Elwyn Griffiths, DSc, PhD, UK

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products

HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT

PRAXIS. A publication by Bioengineering AG

Job Title: Cell Culture Technician (open June 1 through Oct 31, 2016)

Analysis of Protein Biopharmaceuticals

Overview Rentschler Biotechnologie

5.14. GENE TRANSFER MEDICINAL PRODUCTS FOR HUMAN USE. Recombinant vectors Gene transfer medicinal products for human use

Molecular & Virology Services

Optimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk. Feng Gao, MD, PhD. AutekBio CO.

FDA recommendations for comparability studies to support manufacturing changes. Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA

Quality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018

Raw Materials: Sourcing and Qualification Testing

Outline. Upstream Processing: Development & Optimization

Outsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D.

Recombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016

New proposal from the EC:

Precision. Proficiency. Proximity.

Introduction of Development Center for Biotechnology TAIWAN

QPCR in Biopharmaceuticals & Current Issues. Chaminda Salgado Head of PCR Services

Position1: Senior Scientist/Principal Scientist

Affigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area Bangalore, Karnataka,India

Guide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia

AAV vectors for gene therapy. Any Gene to Any Cell

Biotechpharma company profile. Romanas Ramanauskas Business development manager

LIFE SCIENCES LABORATORY SERVICES

Services for Medical Devices. Expert solutions for product development from concept to commercialization

Recommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines

Gala s Gene Product Expression (GPEx ) Platform

Reference Materials for Adeno-Associated Viruses

Opportunities for Accelerating Cell Line Development and Beyond

QA Production Material and Analytical Methods. BIT 230 Chapters 5 and 6 (Huxsoll)

Rapid selection of high yielding GS-CHO cell lines using the GS expression system in a protein-free, chemically defined, animal component-free process

Fast decisions instead of delays Quality Control through outstanding design

BIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE

Detection and Quantitation of Residual Host Cell DNA

Regulatory Considerations on. Office of Biotechnology Products

cgmp Cell & Gene Therapy

Biotechnology: Quality Assurance and Validation

BRUSSELS CORDENPHARMA EXPERTS TAKING CARE

CORDENPHARMA BRUSSELS EXPERTS TAKING CARE

European Medicines Agency

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Product Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006

Manufacturing Integrated Biologics Manufacturing

sterility assurance Prove the power and your processes

Welcome Biotech 101. Outline. Before the Floor. Manufacturing Process. Supporting Cast 4/22/2013

Preclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015

BSA FRACTION V BOVINE SERUM ALBUMIN

Supplies and Reagents

The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives

In ensuring the safety of veterinary vaccines demonstration of freedom from EA is one of high importance.

The new innovations of mab biolimilars and antibody therapeutics Our dedication to human health

Preparing the CMC section of IMPD for biological/biotechnology derived substances

A Regulatory Perspective on Characterization and Control of Process-Related Impurities

Guidance for FDA Review Staff and Sponsors

The country of origin for FBS refers to country in which the raw blood was collected.

Supplies and Reagents

Global Biological Resource Leader

Risk Mitigation in Cell Culture: How to Prevent Viral Contamination

Reference Standards for Monoclonal Antibodies: Key Challenges Addressed

Global Sterile Liquid Capabilities

Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)

PRODUCTION AND QUALITY CONTROL OF CYTOKINE PRODUCTS DERIVED BY BIOTECHNOLOGICAL PROCESSES

SUBMISSION OF COMMENTS ON GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS - EMEA/CHMP/BWP/398498/2005

Vaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study.

CHOgro Expression System

Virus Filtration for Biosimilars : From needs to Solutions

NEWS. Bio/Pharmaceutical

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials

Switzerland EXPERTS TAKING CARE

Annex 4. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology

Virosart Media. Upstream Virus Retentive Filter. Product Information

High Purity Water, Buffers and Custom Solution Manufacturing Services

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials

GMP. Safeguard The Patient s Health.

Laboratory Reagents. for life science research.

Antibody-Drug Conjugate Characterization and Quality Assurance

Manufacturing Viral Gene Therapy Vectors: General Approaches and Challenges John T. Gray

Module 1 overview PRESIDENTʼS DAY

Subject Index. chromatography step, 125-

Abstract. Materials and Methods. Introduction

BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS

Transcription:

Cell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products

Founded in 96, Eurofins Lancaster Laboratories is a global leader in comprehensive laboratory services enabling pharmaceutical and biopharmaceutical companies to advance candidates from development through commercialization while ensuring regulatory compliance, cost effectiveness and achievement of timelines.

A global leader in biopharmaceutical laboratory services, Eurofins Lancaster Laboratories provides you with the tools and support to better manage your biopharmaceutical development process. Our vast capacity and extensive capabilities provide the greatest breadth of cgmp-compliant biopharmaceutical services in the industry. Eurofins Lancaster Laboratories offers capabilities to prepare and characterize a wide variety of mammalian, insect and avian cell banks, including master, working and research banks. Our cgmp-compliant facilities include multiple Grade A/B suites and ISO 7 clean rooms with ISO 5 critical areas designed to meet current FDA aseptic processing guidelines. We also offer a comprehensive package of safety testing services in the areas of microbiology, mycoplasma, genetic stability, viral safety and biochemistry to support our cell banking capabilities. All of these services are provided with strict adherence to cgmp requirements and are designed to fully support the testing of your biopharmaceutical product, including the testing of raw materials, cell lines, unprocessed bulk, purified bulk and final product. This document provides Eurofins Lancaster Laboratories recommendations for cell line characterization, safety evaluation and product testing for a CHO-derived biopharmaceutical product. It outlines a testing strategy that should satisfy the latest guidance of global regulatory authorities, including the FDA and EMA. However, it may not be necessary to conduct all of the tests listed. We highly recommend a discussion to evaluate those factors that can influence which tests can be omitted or whether additional testing might be required based on our experience. The combination of our manufacturing capabilities with our extensive characterization services provide you with a single-source solution for all of your cell line and product testing needs.

Cell Seed Testing Test Identity Genetic Stability Sterility Mycoplasma Viruses Bacteriostasis/Fungistasis by Direct Transfer Sterility Testing - Non Isolator Mycoplasmastasis Additional testing may be advised after a technical discussion. For example, identity testing may be performed to ensure the cells are the correct species before production of the MCB. Limited viral screening may also be completed during this phase to mitigate risk. Container ingress studies may be required prior to performance of the sterility test in isolators. Alternatively, a non-isolator sterility test may be performed. Master Cell Bank Testing Test Identity Genetic Stability Sterility Mycoplasma Viruses CO/Cyt B Sizing or CO Barcoding Copy Number by qpcr Restriction Mapping by Southern Blot DNA Sequencing Bacteriostasis/Fungistasis by Direct Transfer Sterility by Direct Transfer Mycoplasmastasis In Vitro Adventitious Viruses (8 day test, cell lines) In Vitro Adventitious Viruses for MMV (8 day test, cell line) In Vivo Adventitious Viruses 8 Transmission Electron Microscopy 4 Reverse Transcriptase Assay, 5 S + L - Focus Forming Assay for enotropic Retroviruses Hamster Antibody Production (HAP) 8 Mouse Antibody Production (MAP) 8 Detection of MMV DNA by qpcr 9 Porcine Viruses by 9CFR, 6 Bovine Viruses 9CFR, 7 A technical discussion is required to determine an appropriate approach to genetic stability testing. Bacteriostasis/fungistasis and mycoplasmastasis may not be required if the results from seed cell testing are applicable to the MCB. A technical discussion is recommended to discuss matrix interference testing for this assay. 4 This assay is subcontracted to an approved vendor and performed as a GLP assay. 5 Reverse Transcriptase Testing should be discussed further as a positive result is not unexpected with CHO cells. 6 Porcine 9CFR testing is advised if the cells have ever been in contact with porcine trypsin or any other porcine-derived product. 7 Bovine 9CFR testing is advised if the cells have ever been in contact with bovine serum or any other bovine-derived product. 8 This assay is subcontracted to an approved vendor. 9 A technical discussion is recommended to discuss matrix interference testing for this assay. Other viral qpcr assays are available upon request.

Working Cell Bank Testing CO/Cyt B Sizing or CO Barcoding Test Identity Genetic Stability Sterility Mycoplasma Viruses Bacteriostasis/Fungistasis by Direct Transfer Sterility by Direct Transfer Mycoplasmastasis In Vitro Adventitious Viruses (4 or 8 day test, cell lines) In Vitro Adventitious Viruses for MMV (8 day test, cell line) In Vivo Adventitious Viruses Bacteriostasis/fungistasis and mycoplasmastasis may not be required if the results from seed cell and/or MCB testing are applicable to the WCB. A technical discussion is recommended to discuss matrix interference testing for this assay. In vivo adventitious test is not required if this testing will be done on EOP cells. Also see footnote under unprocessed bulk testing. This assay is subcontracted to an approved vendor. End of Production Cell Bank Testing (Cells at Limit of In-Vitro Age) CO/Cyt B Sizing or CO Barcoding Copy Number by qpcr Restriction Mapping by Southern Blot DNA Sequencing Test Identity Genetic Stability Sterility Mycoplasma Viruses Bacteriostasis/Fungistasis by Direct Transfer Sterility Testing - Non Isolator Mycoplasmastasis In Vitro Adventitious Viruses (8 day test, cell lines) In Vitro Adventitious Viruses for MMV (8 day test, cell line) In Vivo Adventitious Viruses Transmission Electron Microscopy Reverse Transcriptase Assay, 4 S + L - Focus Forming Assay for enotropic Retroviruses Hamster Antibody Production (HAP) Mouse Antibody Production (MAP) Detection of MMV DNA by qpcr 7 Porcine Viruses by 9CFR, 5 Bovine Viruses by 9CFR, 6 A technical discussion is required to determine an appropriate approach to genetic stability testing. A technical discussion is recommended to discuss matrix interference testing for this assay. This assay is subcontracted to an approved vendor and performed as a GLP assay. 4 Reverse Transcriptase Testing should be discussed in more detail as a positive result is not unexpected with CHO cells. 5 Porcine 9CFR testing is advised if the cells have ever been in contact with porcine trypsin or any other porcine-derived product. 6 Bovine 9CFR testing is advised if the cells have ever been in contact with bovine serum or any other bovine-derived product. 7 A technical discussion is recommended to discuss matrix interference testing for this assay. Other viral qpcr assays are available upon request.

Unprocessed Bulk Testing Test Identity Genetic Stability Sterility Mycoplasma Viruses Bacteriostasis/Fungistasis by Direct Transfer Sterility by Direct Transfer Mycoplasmastasis In Vitro Adventitious Viruses (8 day test, cell lines) In Vitro Adventitious Viruses for MMV (8 day test, cell line) In Vivo Adventitious Viruses Transmission Electron Microscopy 4 Detection of MMV DNA by qpcr 5 Testing for bioburden may be more appropriate than sterility testing. A technical discussion is recommended to discuss matrix interference testing for this assay. Other viral qpcr assays available upon request. In vivo testing of the unprocessed bulk is unusual but may be requested by a regulator as one-time testing or after a change in bioreactor conditions has been made. In vivo testing is also performed if EOP cells are not tested during early stages of product development. This assay is subcontracted to an approved vendor. 4 This assay is performed as a GLP assay and is typically performed only on the first three consecutive lots. 5 A technical discussion is recommended to discuss matrix interference testing for this assay. Other viral qpcr assays available upon request. Purified Bulk & Final Product Testing Test Bacteriostasis/Fungistasis Sterility by Direct Transfer Bacterial Endotoxin General Safety Test Residual CHO DNA by qpcr CHO Host Cell Protein by ELISA Protein A by ELISA Amino Acid Analysis Appearance of Solution Biopotency Assay Carbohydrate Mapping Monosaccharide Analysis Protein Content Assay Analysis by HPLC Moisture by Karl Fischer N-Terminal Sequencing Osmolality Peptide Mapping ph Determination SDS-PAGE UV Absorbance Western Blot Identity Genetic Stability Sterility Mycoplasma Viruses General Safety Residual Impurity Analytical Assays Endotoxin testing is for final product only. This assay is subcontracted to an approved vendor. A technical discussion with regard to analytical testing is advised. The tests listed are examples of the types of tests offered and which are often requested by clients.

Test TAT* Sample Requirements Storage Amino Acid Analysis 0 business days >0 mg powder -0ºC or below Analysis by HPLC (ion exchange separation) 0 business days > mg -0ºC or below Analysis by HPLC (reverse phase separation) 0 business days > mg -0ºC or below Analysis by HPLC (size exclusion separation) 0 business days > mg º to 8ºC Appearance of Solution 0 business days variable variable Bacterial Endotoxin - Inhibition/Enhancement 0 business days -5 ml variable Bacterial Endotoxin 0 business days -5 ml variable Bacteriostasis/Fungistasis 7 business days variable variable Biopotency Assay weeks 0.5- ml if in liquid form, 5 mg solid API variable Bovine Viruses 5 weeks 8 ml cell lysate at E7 cells/ml -60ºC or below Carbohydrate Mapping 0 business days > mg -0ºC or below CHO Host Cell Protein by ELISA weeks ml if in liquid form, 5 mg solid API -60ºC or below Copy Number by qpcr weeks x E7 cell pellet -60ºC or below Detection of MMV DNA by qpcr weeks 4 ml for matrix qualification, ml for routine -0ºC or below DNA Sequencing Custom E7 cell pellet if nonbacterial, glycerol stock or E8 cell pellet if bacterial -60ºC or below General Safety Test 4 weeks 5 ml variable Hamster Antibody Production (HAP) 7 weeks 5 ml cell lysate at E7 cells/ml -60ºC or below CO/Cyt B Sizing 0 business days E7 cells -60ºC or below CO Barcoding 5 business days E7 cells -60ºC or below In Vivo Adventitious Viruses 7 Weeks +8++ ml bulk harvest or cell lysate at E7 cells/ml -60ºC or below In Vitro Adventitious Viruses (8 day test, cell lines) 6 weeks 0 ml bulk harvest or cell lysate at E7 cells/ml -60ºC or below In Vitro Adventitious Viruses for MMV (8 day test, cell line) 6 weeks 7 ml bulk harvest or cell lysate at E7 cells/ml -60ºC or below Moisture by Karl Fischer weeks variable variable Monosaccharide Analysis 0 business days > mg -0ºC or below Mouse Antibody Production (MAP) 7 weeks 5 ml cell lysate at E7 cells/ml -60ºC or below Mycoplasma (Cells) 5 business days x ml, x.5 ml > x 0 6 cells/ml -60ºC without cryoprotectant Mycoplasmastasis (Cells) 0 business days x 5 ml, 4 x.5 ml > x 0 6 cells/ml -60ºC without cryoprotectant Mycoplasma (Unprocessed Bulk) 5 business days x ml, x.5 ml -60ºC Mycoplasmastasis (Unprocessed Bulk) 0 business days x 5 ml, 4 x.5 ml -60ºC N-Terminal Sequencing 0 business days 0.5 mg protein -0ºC or below Oligosaccharide Profile (Glycan Analysis) 0 business days 0.5 mg protein -0ºC or below Osmolality 0 business days variable -0ºC or below Peptide Mapping 0 business days > mg -0ºC or below ph Determination 0 business days variable -0ºC or below Porcine Viruses 5 weeks 0 ml cell lysate at E7 cells/ml -60ºC or below Protein A by ELISA Weeks ml if in liquid form, 5 mg solid API -60ºC or below Protein Content Assay 0 business days dependent on extinction coefficient -0ºC or below Residual CHO DNA by qpcr weeks 4 ml for matrix qualification, ml for routine -0ºC or below Restriction Mapping by Southern Blot 6-8 weeks E7-4E7 cell pellet -60ºC or below Reverse Transcriptase Assay weeks ml supernatant for matrix qualification, ml routine -60ºC or below S + L - Focus Forming Assay for enotropic Retroviruses 5 weeks 5 ml culture supernatant -60ºC or below SDS-PAGE 0 business days 0.5 mg protein -0ºC or below Sterility 7 business days variable variable Transmission Electron Microscopy (Cells) 0- weeks fixed cell pellet, at least E7 cells º to 8ºC Transmission Electron Microscopy (Supernatant) 0- weeks 0 ml bioreactor harvest -60ºC or below UV Absorbance 0 business days dependent on ext. coeff. -0ºC or below Western Blot 0 business days 0.5mg protein -0ºC or below * Standard turnaround time. Expedited turnaround may be available with prior notification.

Global Services: Chemistry/Biochemistry Cell Banking Services Facility & Process Validation Method Development & Validation Microbiology Molecular & Cell Biology Raw Materials Testing Release Testing Residuals & Impurities Testing Stability Testing & Storage Viral Clearance & Viral Safety Professional Scientific Services Facilities: Lancaster, PA 77-656-00 Portage, MI 69--66 Dungarvan, Ireland 5 (0) 58 4800 A member of the Eurofins BioPharma Product Testing Group The largest network of harmonized bio/pharmaceutical GMP product testing labs worldwide. www.eurofinslancasterlabs.com 9 5